{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:33:16Z","timestamp":1792899196447,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,6,3]],"date-time":"2009-06-03T00:00:00Z","timestamp":1243987200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1471-2334-9-81","type":"journal-article","created":{"date-parts":[[2009,8,7]],"date-time":"2009-08-07T09:44:57Z","timestamp":1249638297000},"source":"Crossref","is-referenced-by-count":63,"title":["Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda"],"prefix":"10.1186","volume":"9","author":[{"given":"Laurence","family":"Ahoua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunar","family":"Guenther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretxu","family":"Pinoges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Anguzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Chaix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Le Tiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suna","family":"Balkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Olaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Pujades-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,6,3]]},"reference":[{"key":"846_CR1","unstructured":"UNAIDS: Epidemiological fact sheets on HIV\/AIDS and STIs. Uganda; 2008 update. [ http:\/\/www.unaids.org\/en\/Regions_Countries\/Countries\/Uganda.asp ]"},{"key":"846_CR2","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1089\/08892220260387922","volume":"18","author":"A Kebba","year":"2002","unstructured":"Kebba A, Atwine D, Mwebaze R, Kityo C, Nakityo R, Peter M: Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients. AIDS Res Hum Retroviruses. 2002, 18: 1181-1187. 10.1089\/08892220260387922.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"846_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S0140-6736(02)09330-3","volume":"360","author":"PJ Weidle","year":"2002","unstructured":"Weidle PJ, Malamba S, Mwebaze R, et al: Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 2002, 360: 34-40. 10.1016\/S0140-6736(02)09330-3.","journal-title":"Lancet"},{"key":"846_CR4","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1097\/01.aids.0000233572.59522.45","volume":"20","author":"DART Virology Group and Trial Team","year":"2006","unstructured":"DART Virology Group and Trial Team: Virological response to a triple nucleoside\/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS. 2006, 20: 1391-1399.","journal-title":"AIDS"},{"key":"846_CR5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/01.qai.0000134742.26338.2f","volume":"38","author":"C Kabugo","year":"2005","unstructured":"Kabugo C, Bahendeka S, Mwebaze R, et al: Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4+ cell count responses. J Acquir Immune Defic Syndr. 2005, 38: 578-583. 10.1097\/01.qai.0000134742.26338.2f.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"846_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1086\/499044","volume":"42","author":"LA Spacek","year":"2006","unstructured":"Spacek LA, Shihab HM, Kamya MR, et al: Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis. 2006, 42: 252-259. 10.1086\/499044.","journal-title":"Clin Infect Dis"},{"key":"846_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/QAI.0b013e31814278c0","volume":"46","author":"MR Kamya","year":"2007","unstructured":"Kamya MR, Mayanja-Kizza H, Kambugu A, et al: Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007, 46: 187-193. 10.1097\/QAI.0b013e31814278c0.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"846_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(06)69158-7","volume":"368","author":"CF Gilks","year":"2006","unstructured":"Gilks CF, Crowley S, Ekpini R, et al: The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006, 368: 505-510. 10.1016\/S0140-6736(06)69158-7.","journal-title":"Lancet"},{"key":"846_CR9","volume-title":"Scaling up access to antiretroviral therapy in Resource-limited settings: treatment guidelines for a public health approach. 2003 revision","author":"World Health Organization","year":"2004","unstructured":"World Health Organization: Scaling up access to antiretroviral therapy in Resource-limited settings: treatment guidelines for a public health approach. 2003 revision. 2004, Geneva: WHO"},{"key":"846_CR10","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0140-6736(06)68580-2","volume":"367","author":"L Ferradini","year":"2006","unstructured":"Ferradini L, Jeannin A, Pinoges L, et al: Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006, 367: 1335-1342. 10.1016\/S0140-6736(06)68580-2.","journal-title":"Lancet"},{"key":"846_CR11","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/00002030-200404090-00006","volume":"18","author":"D Coetzee","year":"2004","unstructured":"Coetzee D, Hildebrand K, Boulle A, et al: Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004, 18: 887-895. 10.1097\/00002030-200404090-00006.","journal-title":"AIDS"},{"key":"846_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0378-4347(97)00193-X","volume":"695","author":"EY Wu","year":"1997","unstructured":"Wu EY, Wilkinson JM, Naret DG, et al: High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. J Chromatogr B Biomed Sci Appl. 1997, 695: 373-380. 10.1016\/S0378-4347(97)00193-X.","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"846_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0378-4347(98)00217-5","volume":"713","author":"RP van Heeswijk","year":"1998","unstructured":"van Heeswijk RP, Hoetelmans RM, Meenhorst PL, Mulder JW, Beijnen JH: Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1998, 713: 395-399. 10.1016\/S0378-4347(98)00217-5.","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"846_CR14","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1128\/JCM.43.6.2709-2717.2005","volume":"43","author":"F Rouet","year":"2005","unstructured":"Rouet F: Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol. 2005, 43: 2709-2717. 10.1128\/JCM.43.6.2709-2717.2005.","journal-title":"J Clin Microbiol"},{"key":"846_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/01.qai.0000155201.51232.2e","volume":"38","author":"D Descamps","year":"2005","unstructured":"Descamps D: French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-na\u00efve chronically infected patients in 2001\u20132002. J Acquir Immune Defic Syndr. 2005, 38: 545-552. 10.1097\/01.qai.0000155201.51232.2e.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"846_CR16","unstructured":"ANRS: The French ANRS (National Agency for AIDS Research) AC11 HIV-1 Resistance Group: HIV-1 genotypic drug resistance interpretation algorithms. [ http:\/\/www.hivfrenchresistance.org ]"},{"key":"846_CR17","volume-title":"Division of AIDS table for grading the severity of adult and pediatric adverse events","author":"AIDS Clinical Trial Group","year":"2004","unstructured":"AIDS Clinical Trial Group: Division of AIDS table for grading the severity of adult and pediatric adverse events. 2004, [ http:\/\/www.aactg.org\/ ]"},{"key":"846_CR18","volume-title":"Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach","author":"World Health Organization","year":"2006","unstructured":"World Health Organization: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006, Geneva: WHO"},{"key":"846_CR19","volume-title":"WHO consultation on ART failure in the context of public health approach. Draft meeting report","author":"World Health Organization","year":"2008","unstructured":"World Health Organization: WHO consultation on ART failure in the context of public health approach. Draft meeting report. 2008, Geneva: WHO"},{"key":"846_CR20","first-page":"171","volume-title":"Prise en charge m\u00e9dicale des personnes infect\u00e9es par le VIH. Rapport 2006, Recommandations du groupe d'experts Sous la direction du Professeur Patrick Yeni","author":"AM Taburet","year":"2006","unstructured":"Taburet AM, Garrafo R, Goujard C, Molina M, Peytavin G, Treluyer JM: [Pharmacologie des Antir\u00e9troviraux: Indications des dosages plasmatiques des antir\u00e9troviraux]. Prise en charge m\u00e9dicale des personnes infect\u00e9es par le VIH. Rapport 2006, Recommandations du groupe d'experts Sous la direction du Professeur Patrick Yeni. Edited by: Flammarion SA, Direction G\u00e9n\u00e9rale de la Sante ANRS. 2006, Paris: R\u00e9publique Fran\u00e7aise. Minist\u00e8re de la Sant\u00e9 et des solidarit\u00e9s, 171-184."},{"key":"846_CR21","volume-title":"Epidemiologie, principes et m\u00e9thodes quantitatives","author":"J Bouyer","year":"1995","unstructured":"Bouyer J, H\u00e9mon D, Cordier S, et al: Epidemiologie, principes et m\u00e9thodes quantitatives. 1995, INSERM ed. Paris"},{"issue":"Suppl 3","key":"846_CR22","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1097\/00002030-200317003-00002","volume":"17","author":"G Djomand","year":"2003","unstructured":"Djomand G, Roels T, Ellerbrock T, et al: Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS. 2003, 17 (Suppl 3): S5-S15.","journal-title":"AIDS"},{"key":"846_CR23","first-page":"320","volume":"84","author":"E Libamba","year":"2006","unstructured":"Libamba E, Makombe S, Mhango E, et al: Supervision, monitoring and evaluation of nationwide scale-up of antiretroviral therapy in Malawi. Bull World Health Organ. 2006, 84: 320-326.","journal-title":"Bull World Health Organ"},{"key":"846_CR24","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.296.7.782","volume":"296","author":"JS Stringer","year":"2006","unstructured":"Stringer JS, Zulu I, Levy J, et al: Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006, 296: 782-793. 10.1001\/jama.296.7.782.","journal-title":"JAMA"},{"key":"846_CR25","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(06)68337-2","volume":"367","author":"P Braitstein","year":"2006","unstructured":"Braitstein P, Brinkhof MW, Dabis F, et al: Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006, 367: 817-824. 10.1016\/S0140-6736(06)68337-2.","journal-title":"Lancet"},{"key":"846_CR26","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/01.aids.0000226959.87471.01","volume":"20","author":"JF Etard","year":"2006","unstructured":"Etard JF, Ndiaye I, Thierry-Mieg M, et al: Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006, 20: 1181-1189. 10.1097\/01.aids.0000226959.87471.01.","journal-title":"AIDS"},{"key":"846_CR27","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1097\/QAD.0b013e32801086b0","volume":"20","author":"R Zachariah","year":"2006","unstructured":"Zachariah R, Fitzgerald M, Massaquoi M, et al: Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS. 2006, 20: 2355-2360. 10.1097\/QAD.0b013e32801086b0.","journal-title":"AIDS"},{"key":"846_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.nut.2004.09.013","volume":"21","author":"G Anabwani","year":"2005","unstructured":"Anabwani G, Navario P: Nutrition and HIV\/AIDS in sub-Saharan Africa: an overview. Nutrition. 2005, 21: 96-99. 10.1016\/j.nut.2004.09.013.","journal-title":"Nutrition"},{"key":"846_CR29","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/S0140-6736(06)69117-4","volume":"368","author":"M Badri","year":"2006","unstructured":"Badri M, Lawn SD, Wood R: Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet. 2006, 368: 1254-1259. 10.1016\/S0140-6736(06)69117-4.","journal-title":"Lancet"},{"key":"846_CR30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.7326\/0003-4819-133-6-200009190-00013","volume":"133","author":"JA DeSimone","year":"2000","unstructured":"DeSimone JA, Pomerantz RJ, Babinchak TJ: Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med. 2000, 133: 447-454.","journal-title":"Ann Intern Med"},{"key":"846_CR31","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(06)69573-1","volume":"368","author":"NR Gandhi","year":"2006","unstructured":"Gandhi NR, Moll A, Sturm AW, et al: Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006, 368: 1575-1580. 10.1016\/S0140-6736(06)69573-1.","journal-title":"Lancet"},{"key":"846_CR32","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S0140-6736(06)69118-6","volume":"368","author":"PJ Weidle","year":"2006","unstructured":"Weidle PJ, Wamai N, Solberg P, et al: Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet. 2006, 368: 1587-1594. 10.1016\/S0140-6736(06)69118-6.","journal-title":"Lancet"},{"key":"846_CR33","first-page":"211","volume":"39","author":"C Diamond","year":"2005","unstructured":"Diamond C, Richardson JL, Milam J, et al: Use of and adherence to antiretroviral therapy is associated with decreased sexual risk behavior in HIV clinic patients. J Acquir Immune Defic Syndr. 2005, 39: 211-218.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"846_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/1055329004269283","volume":"15","author":"J Russell","year":"2004","unstructured":"Russell J, Krantz S, Neville S: The patient-provider relationship and adherence to highly active antiretroviral therapy. J Assoc Nurses AIDS Care. 2004, 15: 40-47. 10.1177\/1055329004269283.","journal-title":"J Assoc Nurses AIDS Care"},{"key":"846_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/00126334-200501010-00003","volume":"38","author":"C Laurent","year":"2005","unstructured":"Laurent C, Ngom Gueye NF, Ndour CT, et al: Long-term benefits of highly active antiretroviral therapy in senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr. 2005, 38: 14-17. 10.1097\/00126334-200501010-00003.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"846_CR36","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/QAI.0b013e31802bf109","volume":"44","author":"PS Sow","year":"2007","unstructured":"Sow PS, Otieno LF, Bissagnene E, et al: Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries. J Acquir Immune Defic Syndr. 2007, 44: 262-267. 10.1097\/QAI.0b013e31802bf109.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"846_CR37","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1097\/00002030-200107270-00006","volume":"15","author":"JA Bartlett","year":"2001","unstructured":"Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F: Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001, 15: 1369-1377. 10.1097\/00002030-200107270-00006.","journal-title":"AIDS"},{"key":"846_CR38","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1097\/QAD.0b013e32828cc8b7","volume":"21","author":"L Ferradini","year":"2007","unstructured":"Ferradini L, Laureillard D, Prak N, et al: Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS. 2007, 21: 2293-2301. 10.1097\/QAD.0b013e32828cc8b7.","journal-title":"AIDS"},{"key":"846_CR39","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/jac\/dkm484","volume":"61","author":"K Cohen","year":"2008","unstructured":"Cohen K, Van CG, Boulle A, et al: Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother. 2008, 61: 389-393. 10.1093\/jac\/dkm484.","journal-title":"J Antimicrob Chemother"},{"key":"846_CR40","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/135965350501000809","volume":"10","author":"RS Autar","year":"2005","unstructured":"Autar RS, Wit FW, Sankote J, et al: Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther. 2005, 10: 937-943.","journal-title":"Antivir Ther"},{"key":"846_CR41","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/00042560-200112150-00007","volume":"28","author":"E Ribera","year":"2001","unstructured":"Ribera E, Pou L, Lopez RM, et al: Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr. 2001, 28: 450-453.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"846_CR42","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1097\/00002030-199912030-00029","volume":"13","author":"GL Dean","year":"1999","unstructured":"Dean GL, Back DJ, de RA: Effect of tuberculosis therapy on nevirapine trough plasma concentrations. AIDS. 1999, 13: 2489-2490. 10.1097\/00002030-199912030-00029.","journal-title":"AIDS"},{"key":"846_CR43","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/jama.300.5.530","volume":"300","author":"A Boulle","year":"2008","unstructured":"Boulle A, Van CG, Cohen K, et al: Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA. 2008, 300: 530-539. 10.1001\/jama.300.5.530.","journal-title":"JAMA"},{"key":"846_CR44","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1365-3156.2005.01409.x","volume":"10","author":"JJ van Oosterhout","year":"2005","unstructured":"van Oosterhout JJ, Bodasing N, Kumwenda JJ, et al: Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health. 2005, 10: 464-470. 10.1111\/j.1365-3156.2005.01409.x.","journal-title":"Trop Med Int Health"},{"key":"846_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000073664","volume":"69","author":"J Donnerer","year":"2003","unstructured":"Donnerer J, Kronawetter M, Kapper A, Haas I, Kessler HH: Therapeutic drug monitoring of the HIV\/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. Pharmacology. 2003, 69: 197-204. 10.1159\/000073664.","journal-title":"Pharmacology"},{"key":"846_CR46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1128\/AAC.43.1.121","volume":"43","author":"XJ Zhou","year":"1999","unstructured":"Zhou XJ, Sheiner LB, D'Aquila RT, et al: Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1999, 43: 121-128.","journal-title":"Antimicrob Agents Chemother"},{"key":"846_CR47","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1001\/jama.296.6.679","volume":"296","author":"EJ Mills","year":"2006","unstructured":"Mills EJ, Nachega JB, Buchan I, et al: Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006, 296: 679-690. 10.1001\/jama.296.6.679.","journal-title":"JAMA"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-9-81\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-81.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-81","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-81.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T08:13:16Z","timestamp":1685088796000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-9-81"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,3]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["846"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-9-81","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,3]]},"article-number":"81"}}